Why did AstraZeneca's stock drop nearly 9.2% on the day, and what was the specific clinical trial failure that triggered it?

AstraZeneca's stock dropped 9.2% because its nerve disease drug Wainua—developed in partnership with U.S.-based Ionis—failed to meet the main goal of reducing cardiovascular deaths and recurring heart problems in a late-stage trial.

What were the contrasting performances of the FTSE 100 and FTSE 250 indices on Thursday, and what key sector movements drove those changes?

The FTSE 100 fell 0.6% to 10,417.63 points, dragged down by pharmaceutical shares (down 6.2%, led by AstraZeneca) and energy stocks (down 1%), while the FTSE 250 rose 0.1%, lifted by strong gains in Playtech (+17.7%) and Computacenter (+7%+), reflecting divergent sector dynamics between blue-chip underperformance and midcap resilience.

London's FTSE 100 Slips as Middle East Tensions Persist, AstraZeneca Drags

Jul 9, 2026

The FTSE 100 fell 0.6% amid Middle East tensions, dragged down by AstraZeneca after its nerve disease drug failed a late-stage trial. Oil prices rose marginally following U.S. strikes on Iran, impacting energy sector performance.

reuters

2026-07-09

European Shares Gain as Tech Stocks Rebound; Middle East in Focus

2026-07-09

London's FTSE 100 Slips as Middle East Tensions Persist, AstraZeneca Drags

2026-07-23

AstraZeneca 'Magic' Faces Rare Test After Trial Failure, Shares Slide

2026-09-17

AstraZeneca-Daiichi breast cancer drug cleared for NHS use in England

London's FTSE 100 Slips as Middle East Tensions Persist, AstraZeneca Drags

FAQ